P Rajagopalan to Lymphocyte Function-Associated Antigen-1
This is a "connection" page, showing publications P Rajagopalan has written about Lymphocyte Function-Associated Antigen-1.
Connection Strength
0.071
-
A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007 Jul; 7(7):1770-7.
Score: 0.071
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.